Respiratory investigation最新文献

{"title":"To coexist or not to coexist: The evolutionary paradox of the human-microbe relationship","authors":"Hajime Fujimoto","doi":"10.1016/j.resinv.2025.101350","DOIUrl":"10.1016/j.resinv.2025.101350","url":null,"abstract":"","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101350"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Long-term effects of inhaled treprostinil in Japanese patients with pulmonary hypertension associated with interstitial lung disease” [Respir Invest, Volume 64, Issue 1, January 2026, 101340]","authors":"Yasuhiro Kondoh , Takashi Ogura , Osamu Nishiyama , Hideyuki Kinoshita , Takeshi Ogo , Nobuhiro Tanabe , Shun Minatsuki , Kazuhiko Nakayama , Yu Taniguchi , Kenta Takahashi , Takashi Orido , Seiichiro Sakao","doi":"10.1016/j.resinv.2025.101365","DOIUrl":"10.1016/j.resinv.2025.101365","url":null,"abstract":"","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101365"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the COVID-19 pandemic on acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study in Japan","authors":"Yuichi Ohteru ,&nbsp;Tomoyuki Kakugawa ,&nbsp;Masahiro Kakugawa ,&nbsp;Tsunahiko Hirano ,&nbsp;Kazuto Matsunaga","doi":"10.1016/j.resinv.2025.11.005","DOIUrl":"10.1016/j.resinv.2025.11.005","url":null,"abstract":"<div><h3>Background</h3><div>The coronavirus disease 2019 (COVID-19) pandemic and associated infection control measures drastically reduced respiratory infections worldwide. This unique context facilitated a natural investigation of the role of respiratory infections in triggering acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). The aim of this study was to evaluate changes in AE-IPF incidence, seasonality, and prognosis before and during the pandemic using a nationwide Japanese database.</div></div><div><h3>Methods</h3><div>This retrospective cohort study was based on hospitalization data from April 1, 2018 to March 31, 2022. Pandemic-related changes in AE-IPF incidence, seasonal trends, and outcomes were assessed with respect to the pre-pandemic period using mixed-design analysis of variance and Kaplan–Meier survival analysis. For comparison, similar changes in chronic obstructive pulmonary disease (COPD) exacerbation were examined using the same methods.</div></div><div><h3>Results</h3><div>Despite reduced respiratory infections, AE-IPF incidence did not decrease during the pandemic. While the typical winter surge in respiratory infections disappeared during the pandemic, the seasonal increase in AE-IPF incidence during winter persisted. However, the incidence of COPD exacerbations decreased significantly, and the seasonality of exacerbations shifted during the pandemic.</div></div><div><h3>Conclusions</h3><div>The findings of this study question the prior assumption that respiratory infections are key contributors to AE-IPF. While respiratory infections may play a role in some cases, our results suggest that, at least for pre-pandemic respiratory infections, their overall contribution may be less substantial than that previously assumed. This underscores the need to reconsider the pathogenesis of AE-IPF and explore noninfectious mechanisms with regard to its management.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101326"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145532470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term effects of inhaled treprostinil in Japanese patients with pulmonary hypertension associated with interstitial lung disease","authors":"Yasuhiro Kondoh ,&nbsp;Takashi Ogura ,&nbsp;Osamu Nishiyama ,&nbsp;Hideyuki Kinoshita ,&nbsp;Takeshi Ogo ,&nbsp;Nobuhiro Tanabe ,&nbsp;Shun Minatsuki ,&nbsp;Kazuhiko Nakayama ,&nbsp;Yu Taniguchi ,&nbsp;Kenta Takahashi ,&nbsp;Takashi Orido ,&nbsp;Seiichiro Sakao","doi":"10.1016/j.resinv.2025.101340","DOIUrl":"10.1016/j.resinv.2025.101340","url":null,"abstract":"<div><h3>Background</h3><div>Treprostinil has been approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) in Japan. This report aimed to evaluate long-term effects of inhaled treprostinil in Japanese patients with PH-ILD based on observation over 52 weeks.</div></div><div><h3>Methods</h3><div>Inhaled treprostinil was administered via a nebulizer from 18 μg (three breaths, four times daily) to 72 μg (12 breaths, four times daily) at minimum 3-day intervals. World Health Organization (WHO) functional class, clinical worsening, adverse events, pulmonary function and ILD-related biomarkers were evaluated throughout the trial.</div></div><div><h3>Results</h3><div>Among 20 patients, 16 and 13 completed the 52-week and 100-week observation periods, respectively. Eleven patients continued on the trial until transitioning to a commercially available product. The reasons of discontinuation in nine patients were adverse events in six patients (including four adverse drug reactions (ADRs)), withdrawal of consent in two patients, and lung transplantation in one patient. The median observation period was 107.5 weeks (interquartile range, 61.4–128.8 weeks) in 20 patients. Among 13 patients observed until week 100, WHO functional class was maintained in 69.2 % (9/13), and improved from class III to class II in 30.8 % (4/13). The main ADRs included cough, malaise, and blood pressure decreased. At the final measurement timepoint in each patient, 70.0 % (14/20) and 83.3 % (15/18) maintained had no absolute decline of forced vital capacity ≥5 % and diffusing capacity for carbon monoxide ≥10 %, respectively.</div></div><div><h3>Conclusion</h3><div>Considering its long-term clinical benefits and tolerability, inhaled treprostinil is a promising treatment option for patients with PH-ILD.</div></div><div><h3>Trial registration</h3><div>Japan Registry of Clinical Trials (jRCT), jRCT2051210016. (first registered: May 7, 2021).</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101340"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features of Mycobacterium abscessus complex and Mycobacterium kansasii pulmonary disease in Kyushu, Japan","authors":"Kazuaki Takeda ,&nbsp;Takahiro Takazono ,&nbsp;Shotaro Ide ,&nbsp;Masataka Yoshida ,&nbsp;Naoki Iwanaga ,&nbsp;Naoki Hosogaya ,&nbsp;Yusei Tsukamoto ,&nbsp;Satoshi Irifune ,&nbsp;Takayuki Suyama ,&nbsp;Asuka Umemura ,&nbsp;Tomo Mihara ,&nbsp;Akira Kondo ,&nbsp;Tsutomu Kobayashi ,&nbsp;Eisuke Sasaki ,&nbsp;Toyomitsu Sawai ,&nbsp;Yasuhito Higashiyama ,&nbsp;Kohji Hashiguchi ,&nbsp;Minako Hanaka ,&nbsp;Toshihiko Ii ,&nbsp;Kiyoyasu Fukushima ,&nbsp;Hiroshi Mukae","doi":"10.1016/j.resinv.2025.101358","DOIUrl":"10.1016/j.resinv.2025.101358","url":null,"abstract":"<div><h3>Background</h3><div>Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a chronic respiratory infection with a growing incidence and mortality globally. Although the clinical features, treatment, and prognosis of <em>Mycobacterium avium-intracellulare</em> (MAI) pulmonary disease have been extensively reported, evidence regarding non-MAI NTM-PD remains limited.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included patients newly diagnosed with NTM-PD between 2010 and 2017 at 18 hospitals in Kyushu, Japan. Data on baseline characteristics, causative organisms, radiological findings, treatment regimens, and clinical outcomes were collected and analysed.</div></div><div><h3>Results</h3><div>In total, 1317 patients were enrolled. <em>M. intracellulare</em> (50.4 %), <em>M. avium</em> (40.5 %), <em>M. abscessus</em> complex (MABC) (2.4 %), and <em>M. kansasii</em> (2.4 %) were identified as the major causative organisms. Compared with patients with MAI, those with MABC exhibited a lower body mass index and a higher AFB sputum smear positivity rate. Patients with <em>M. kansasii</em> infection were predominantly male, frequently had underlying chronic obstructive pulmonary disease, and presented with cavitary lesions. Treatment initiation rates for MABC and <em>M. kansasii</em> were 71.9 % and 87.5 %, respectively. The response rate to the treatment in sputum mycobacterial evaluation was comparable between the two groups. However, the re-treatment rate was higher in the MABC group (30.4 % vs. 14.3 %). The 10-year mortality rates were 25.0 % and 15.6 % for MABC and <em>M. kansasii</em>, respectively.</div></div><div><h3>Conclusions</h3><div>Initial treatment responses for MABC and <em>M. kansasii</em> were favourable. However, long-term outcomes for MABC remained poor, potentially owing to the limited availability of effective continuation-phase therapies. Further large-scale prospective studies are warranted to understand the clinical management and prognosis of non-MAI NTM-PD.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101358"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of hospitalization on health-related quality of life in patients receiving home oxygen therapy: Insights of the Japanese white paper on home respiratory care 2024","authors":"Satoshi Hamada ,&nbsp;Jun Ueki ,&nbsp;Toyohiro Hirai ,&nbsp;Emika Sano ,&nbsp;Keiko Hino ,&nbsp;Megumi Ikeda ,&nbsp;Susumu Sato ,&nbsp;Toru Oga ,&nbsp;Tomomasa Tsuboi ,&nbsp;Hajime Kurosawa ,&nbsp;Hiroo Wada ,&nbsp;the Japanese White Paper on Home Respiratory Care 2024 working group","doi":"10.1016/j.resinv.2025.101341","DOIUrl":"10.1016/j.resinv.2025.101341","url":null,"abstract":"<div><h3>Background</h3><div>There are no available data on the impact of hospitalization on health-related quality of life (HRQoL) in patients receiving home oxygen therapy (HOT). Thus, the present study aimed to examine the association between hospitalization and HRQoL in patients receiving HOT based on the results of the Japanese White Paper on Home Respiratory Care 2024.</div></div><div><h3>Methods</h3><div>Patients receiving HOT who completed the HRQoL section of the patient survey, assessed using the Short Form-8 (SF-8) questionnaire, were included in the analysis. This survey data were collected from December 2021 to March 2023. The SF-8 questionnaire comprised eight subitems and two summary scores (physical component summary [PCS] and mental component summary [MCS]). Hospitalization within the past year were evaluated, excluding those due to coronavirus disease 2019.</div></div><div><h3>Results</h3><div>Totally, 288 patients receiving HOT were examined. In the SF-8 questionnaire survey, all items except body pain and the two summary scores did not differ between patients with chronic obstructive pulmonary disease and those with interstitial lung disease. Patients who had history of hospitalization had lower scores in all eight subitems and in both summary scores than those who did not. Based on a stepwise multiple linear regression analysis, PCS (β = −0.14, p = 0.011) and MCS (β = −0.14, p = 0.014) scores were independently and negatively correlated with hospitalization.</div></div><div><h3>Conclusions</h3><div>A history of hospitalization was independently associated with reduced HRQoL in patients receiving HOT. Prospective studies are needed to clarify underlying mechanisms and to evaluate interventions that may minimize HRQoL decline.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101341"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145616022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of individuals with COPD using biometric voice and cough sound features","authors":"Yasushi Obase ,&nbsp;Susumu Fukahori ,&nbsp;Jun Iriki ,&nbsp;Takahiro Takazono ,&nbsp;Yusei Tsukamoto ,&nbsp;Shinnosuke Takemoto ,&nbsp;Noriho Sakamoto ,&nbsp;Yusuke Hamanaka ,&nbsp;Hideaki Watanabe ,&nbsp;Kazumi Hirano ,&nbsp;Chizu Fukushima ,&nbsp;Tomoya Nishino ,&nbsp;Hiroshi Mukae","doi":"10.1016/j.resinv.2025.101353","DOIUrl":"10.1016/j.resinv.2025.101353","url":null,"abstract":"<div><h3>Background</h3><div>Chronic obstructive pulmonary disease (COPD), a major global health burden linked to smoking, is frequently underdiagnosed due to low awareness and delayed symptom recognition. This study explored the feasibility of non-invasive voice and cough sound analysis for COPD identification.</div></div><div><h3>Methods</h3><div>In this prospective study, 55 participants (26 with COPD, 29 without) underwent pulmonary function testing and provided sociodemographic and clinical data. Speech and cough sounds were recorded three times per participant and processed using acoustic feature extraction, feature selection via the minimum redundancy maximum relevance algorithm, and logistic regression classification. Model performance was evaluated using four-fold cross-validation. Statistical analysis was conducted with JMP software (p &lt; 0.05).</div></div><div><h3>Results</h3><div>The vowel sound/u/showed statistically significant discriminatory ability in the mixed-gender cohort, but sensitivity and specificity were both below 80 %, indicating limited diagnostic performance. When restricted to male participants, both metrics exceeded 80 %, suggesting higher discriminatory power. Smartphone recordings yielded comparable accuracy to integrated circuit recorders. Adding COPD assessment test scores and smoking history did not improve classification.</div></div><div><h3>Conclusions</h3><div>Voice analysis may offer a non-invasive screening approach for COPD. However, this study was limited to male participants and a single disease target, restricting generalizability. Future research will expand to include related respiratory conditions such as bronchiectasis and assess performance across sexes and disease types.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101353"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study","authors":"Yukari Tsubata ,&nbsp;Nobuhiro Kanaji ,&nbsp;Mika Nakao ,&nbsp;Takeshi Masuda ,&nbsp;Masahiro Yamasaki ,&nbsp;Masahiro Kodani ,&nbsp;Nobuhisa Ishikawa ,&nbsp;Toshiyuki Kozuki ,&nbsp;Masaaki Inoue ,&nbsp;Kazuya Nishii ,&nbsp;Katsuyuki Hotta ,&nbsp;Katsuyuki Kiura ,&nbsp;Takeshi Isobe","doi":"10.1016/j.resinv.2025.11.011","DOIUrl":"10.1016/j.resinv.2025.11.011","url":null,"abstract":"<div><h3>Background</h3><div>Venous thromboembolism (VTE) is a frequent complication of cancer-associated thrombosis, and its management is critical when considering cancer treatment selection and prognosis. The aim of this study was to investigate the incidence and risk factors for VTE in patients with lung cancer using the CS-Lung003 platform, a multicenter prospective observational study of advanced lung cancer.</div></div><div><h3>Methods</h3><div>Patients with a pathologic diagnosis of lung cancer at any stage were included. The incidence of VTE was calculated using the CS-Lung003 database, and risk factors were examined using logistic regression analysis.</div></div><div><h3>Results</h3><div>The analysis included 1744 patients (80 % male). Sixty patients (3.4 %) had VTE at/after enrollment in the CS-Lung003 trial. The median age was 69 years (range 63–76) in the group without VTE and 72 years (range 67–77) in the group with VTE. Adenocarcinoma was diagnosed in 58.7 % of patients in the group without VTE and 46.7 % in the group with VTE. Univariate analysis revealed male sex, body weight, and hypertension as risk factors for VTE. Overall survival was 29.1 months in the group without VTE and 30.6 months in the group with VTE. Among patients with stage IIIB–IV, the VTE group showed significantly longer overall survival compared with the non-VTE group (p = 0.041).</div></div><div><h3>Conclusions</h3><div>The incidence of VTE in this study was low, suggesting that there may have been patients with VTE complications that were not reported in the registry. In addition, most patients with VTE received therapeutic intervention; appropriate diagnosis and treatment may have allowed cancer treatment to continue. Appropriate diagnosis and treatment of VTE might allow lung cancer therapy continuation without compromising survival.</div></div><div><h3>Clinical trial registry/registration number</h3><div>UMIN-CTR/UMIN000026696.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101332"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145571142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological palliative care for patients with interstitial lung disease in Japan: A secondary analysis of a National Survey of Japanese Respiratory Physicians","authors":"Yoshinobu Matsuda ,&nbsp;Tomoyuki Fujisawa ,&nbsp;Tatsuya Morita ,&nbsp;Masanori Mori ,&nbsp;Norimichi Akiyama ,&nbsp;Takafumi Koyauchi ,&nbsp;Mitsunori Miyashita ,&nbsp;Ryo Tachikawa ,&nbsp;Keisuke Tomii ,&nbsp;Hiromi Tomioka ,&nbsp;Satoshi Hagimoto ,&nbsp;Yasuhiro Kondoh ,&nbsp;Yoshikazu Inoue ,&nbsp;Takafumi Suda","doi":"10.1016/j.resinv.2025.11.009","DOIUrl":"10.1016/j.resinv.2025.11.009","url":null,"abstract":"<div><h3>Background</h3><div>Patients with interstitial lung disease (ILD) often experience psychological symptoms. This study aimed to clarify the status of psychological support for patients with ILD in Japan.</div></div><div><h3>Methods</h3><div>We conducted a secondary analysis on a nationwide survey of Japanese respiratory physicians to assess psychological support availability, consultation departments, reasons for palliative care referrals, and opinions on insurance coverage for psychologist-led psychotherapy.</div></div><div><h3>Results</h3><div>Of 1332 respondents, 1023 managed patients with ILD in the previous year. Among them, 34.5 % reported no psychological support availability and 42.9 % reported insufficient support. Psychiatry or psychosomatic medicine departments were consulted by 77.3 %, and palliative care teams by 52.2 %. Anxiety (47.4 %) and depression (44.6 %) were the reasons for palliative care referral. Overall, 93.6 % considered insurance coverage for psychologist-led psychotherapy helpful or essential.</div></div><div><h3>Conclusions</h3><div>Most physicians lack adequate psychological support resources for ILD despite frequent psychological symptoms. Systematic development of support structures and insurance coverage are needed.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101330"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145571139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of ultrasound-guided cervical lymph node biopsy in lung cancer: A scoping review","authors":"L. Thong ,&nbsp;C. Daneshvar ,&nbsp;M. Hassan ,&nbsp;D. Breen","doi":"10.1016/j.resinv.2025.11.010","DOIUrl":"10.1016/j.resinv.2025.11.010","url":null,"abstract":"<div><div>The involvement of cervical lymph nodes in lung cancer occurs frequently. Despite the involvement of this group of lymph nodes reflecting either stage N3 or M1b in patients with non-small cell lung cancer, they do not receive the same amount of attention as mediastinal lymph nodes. Furthermore, these lymph nodes are more accessible for histology samples compared to other group of lymph nodes. Critically, cervical lymph nodes are often missed on CT scans. Neck US and US-guided biopsy of cervical lymph nodes have more established roles in other primary malignancies (e.g. thyroid cancer) and non-malignant diseases. This scoping review explores existing literature on neck US and cervical lymph node biopsy in patients with suspected lung cancer. The role and potentials benefits of neck US and cervical lymph node biopsy in this group of patients is examined. We also explored whether the procedure is being performed routinely by respiratory physicians as part of their lung cancer algorithm.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101331"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145532471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}